Research programme: enterovirus A vaccine - Sentinext Therapeutics

Drug Profile

Research programme: enterovirus A vaccine - Sentinext Therapeutics

Alternative Names: STX 100/Alhydrogel

Latest Information Update: 20 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sentinext Therapeutics
  • Class Enterovirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Enterovirus A infections

Most Recent Events

  • 18 Jul 2017 Enterovirus A vaccine is still in early research for Enterovirus A infection in Malaysia (Parenteral)(ACTRN12617001027303)
  • 17 Jul 2017 Sentinext Therapeutics plans a phase I trial of STX 100/Alhydrogel (In volunteers, Parenteral) in July 2017 (ACTRN12617001027303)
  • 16 Jul 2016 No recent reports of development identified for research development in Enterovirus A infections in Malaysia (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top